RNS & Investor News

Directorate Change Appointment of Peter Wennström as Non-Executive Director

24 November 2015

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing products to tackle obesity, high cholesterol and diabetes, announces the appointment of Peter Wennström as a Non-Executive Director of the Company with effect from 1 January 2016. Peter will replace Dr Mark Wyatt in his position as Non-Executive Director of the Company.

Mr Wennström has over 25 years of experience in international brand management and consultancy in nutrition, health and wellness and is regarded as one of the world's leading experts in functional foods innovation and marketing. He is author of "Four Factors of Success: A Simple Tool to Innovate Healthy Brands" and co-author of The Food & Health Marketing Handbook. He is the founder and owner of The Healthy Marketing Team ("HMT"), an international and multicultural brand strategy consultancy focused on innovation, marketing and branding in food and health. Since its foundation in 2007, HMT has worked on customer projects in around 60 countries worldwide with leading brands such as CocaCola, Pepsi, Danone, Bayer and GSK.

Stephen O'Hara, CEO of OptiBiotix, commented: "Peter's international experience of marketing and brand management in human health and nutrition brings valuable market insight to OptiBiotix at a key stage in the Company's development. As the Company's development programmes progress towards commercialisation, Peter's understanding of brand positioning and value will help translate product benefits to both consumer and corporates alike. The board of OptiBiotix would like to take this opportunity to thank Mark for his significant contribution to the Company during its early development, and since its admission to AIM in 2014, and wishes him well in his other endeavours."

The following information is disclosed pursuant to Schedule 2(g) of the AIM Rules for Companies:

Jan Peter Fredrik Wennström, aged 58, holds or has held in the past 5 years the following directorships or partnerships:



HMT Limited


Mr Wennström does not currently own any shares in the Company.

There is no further information to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.


For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd (Joint Broker)
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002


About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.